MedTrace Logo

Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis

NCT02275299 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2014-10-27

No results posted yet for this study

Summary

This study is intended to evaluate the efficacy and safety of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in patients with active Rheumatoid Arthritis (RA).

Conditions

Interventions

DRUG

Iguratimod

Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

DRUG

Leflunomide

Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

DRUG

Methotrexate

Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275299 on ClinicalTrials.gov